Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?

Chronic hepatitis C virus (HCV) infection represents a global health problem that affects up to 130–150 million people worldwide. The HCV treatment landscape has been transformed recently by the introduction of direct-acting antiviral (DAA) agents that target viral proteins, including the NS3 protea...

Descripción completa

Detalles Bibliográficos
Autores principales: Janardhan, Sujit V, Reau, Nancy S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403691/
https://www.ncbi.nlm.nih.gov/pubmed/25926761
http://dx.doi.org/10.2147/HMER.S79584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403691/
https://www.ncbi.nlm.nih.gov/pubmed/25926761
http://dx.doi.org/10.2147/HMER.S79584

Ejemplares similares